Capmatinib, used in the treatment of carrying MET exon 14 jumping mutation of patients with metastatic non-small-cell lung cancer (NSCLC), including first-line treatment (initial) patients with previously treated patients (governance).
Indications: for the patients with tumor
Specification: 250 mg * 56 grains
Retail price: $800
Note: Capmatinib used in the treatment of carrying MET exon 14 jumping mutation of metastatic non-small cell lung cancer (NSCLC) patients